Opportunities for Healthy Volunteers
Contribute to medical research by participating in studies designed for healthy participants in your selected area.
↓
Matched clinical trials
A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.
Recruiting
Investigated Diseases:Investigated Drugs:
Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Recruiting
Investigated Drugs:
+13
Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab
Not yet recruiting
Investigated Diseases:Investigated Drugs:
Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer
Not yet recruiting
Investigated Diseases:
Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer
Not yet recruiting
Investigated Drugs:
Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors
Not yet recruiting
Investigated Diseases:Investigated Drugs:- (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
- Rmc-6291
- (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
+3
